Merck Serono, a division of Merck, has commenced its Phase III MAESTRO study designed to assess the efficacy and safety profile of TH-302 in combination with gemcitabine in pancreatic adenocarcinoma patients.

The investigational hypoxia-targeted drug, TH-302, is designed to be activated under severe tumour hypoxic conditions caused due to insufficient blood supply resulting from aberrant vasculature.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Commencement of the study has triggered a $30m milestone payment to Threshold Pharmaceuticals from Merck under a license and co-development agreement signed between the two companies.

Threshold chief executive officer Dr Barry Selick said the commencement of the Phase III MAESTRO study has advanced the development of TH-302 to treat cancer patients.

"The investigational hypoxia-targeted drug, TH-302, is designed to be activated under severe tumour hypoxic conditions caused due to insufficient blood supply resulting from aberrant vasculature."

"This marks the second Phase III study of TH-302 in addition to the ongoing Phase III pivotal trial in patients with soft tissue sarcoma," Selick said.

See Also:

"In addition, we continue to explore the potential breadth and activity of TH-302 against a variety of solid tumours and haematological malignancies in multiple ongoing earlier stage clinical trials."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The randomised, placebo-controlled study of TH-302 plus gemcitabine will be compared with placebo plus gemcitabine in around 660 patients with previously untreated, locally advanced unresectable or metastatic pancreatic adenocarcinoma.

The primary efficacy endpoint of the study, which is being conducted under a special protocol assessment with the FDA, is overall survival.

Secondary endpoints are efficacy measured by progression-free survival, overall response rate and disease control rate, as well as assessments of safety and tolerability, pharmacokinetics and biomarkers.